The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
60
Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
Children's Mercy Hospital
Kansas City, Missouri, United States
RECRUITINGNumber of participants who experience adverse reactions to the measles, mumps, and rubella vaccination
Patients will be screened for adverse reactions following vaccine administration
Time frame: Between 0-240 days after vaccine administration
Number of participants with resultant initial seropositivity against measles after vaccination
Serologic response will be measured after vaccine administration.
Time frame: Between 60-240 days after vaccine administration.
Number of participants who experience prolonged seropositivity after vaccine administration
Serologic response will be tested at least 365 days after final vaccine administration
Time frame: Minimum of 365 days after vaccine administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.